Revere Pharmaceuticals is leading the way in the development of new cancer treatments targeting Rac1 GTPase, an important target in the progression of different cancers. R-ketorolac, our lead candidate, is a first-in-class Rac1 inhibitor that shows both clinical and non-clinical evidence of efficacy in ovarian cancer.

We are currently conducting further preclinical evaluation of R-ketorolac and a second candidate, RP-200.

For more information, contact